3-ethoxycarbonyl-pyrrolidine | 81049-27-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 3-ethoxycarbonyl-pyrrolidine
• 英文别名: ethyl pyrrolidine-3-carboxylate；3-carboethoxypyrrolidine；pyrrolidine-3-carboxylic acid ethyl ester；Pyrrolidin-3-carbonsaeure-aethylester；Ethyl-3-pyrrolidincarboxylat；3-Ethoxycarbonyl-pyrrolidin
• CAS: 81049-27-6；81049-29-8
• 化学式: C₇H₁₃NO₂
• 分子量: 143.186
• InChiKey: MPEUOPWWEODARH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.16
• 重原子数：
  10.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  38.33
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  3-ethoxycarbonyl-pyrrolidine 在 盐酸 作用下， 生成 pyrrolidine-3-carboxylic acid hydrochloride
  参考文献：
  名称：

  .beta.-Proline analogs as agonists at the strychnine-sensitive glycine receptor

  摘要：

  3-Carboxy-3,4-dehydropyrrolidine was found to bind with affinity equal to that of glycine in a [H-3]strychnine binding assay. Simple substitution of the 1-, 2-, 4-, or 5-position resulted in marked loss of affinity. A decline in affinity was also found upon enlargement, contraction, or saturation of the 5-membered ring. However, beta-proline and azetidine-3-carboxylic acid retained significant binding affinity. Despite its good affinity in [H-3]strychnine binding, 3-carboxy-3,4-dehydropyrrolidine showed only weak agonist activity in intracellular recordings of cultured murine spinal cord neurons. This apparent lack of correlation between binding and functional results is discussed in light of the current models of the strychnine-sensitive glycine receptor.

  DOI：

  10.1021/jm00080a006
• 作为产物：
  描述：

  1-苄基-吡咯烷 在 Pd(OH)2 作用下， 以 methanol-dichloromethane 、 乙醇 为溶剂， 生成 3-ethoxycarbonyl-pyrrolidine
  参考文献：
  名称：

  Oxadiazoles useful in the treatment of senile dementia

  摘要：

  一类新型噁二唑醇类化合物，其中一个环上的碳原子被非芳香性氮杂环或氮杂双环取代，另一个环上的碳原子被低亲脂性取代基取代；这些化合物是有效的肌氨酸激动剂，并具有良好的中枢神经系统穿透性。因此，这些化合物在治疗神经和精神疾病方面具有用途。

  公开号：

  US05686463A1

文献信息

• [EN] 1-(4-PIPERIDINYL) BENZIMIDAZOLONES AS HISTAMINE H3 ANTAGONISTS<br/>[FR] 1-(4-PIPERIDINYL) BENZIMIDAZOLONES UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR H3 DE L'HISTAMINE
  申请人：SCHERING CORP

  公开号：WO2003103669A1

  公开（公告）日：2003-12-18

  Disclosed are histamine H3 antagonists of the formula (I) wherein R1 is benzimidazolone derivative, M1 and M2 are optionally substituted carbon or nitrogen, R2 includes optionally substituted aryl or heteroaryl, and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula (I). Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula (I) in combination with a H1 receptor antagonist.

  揭示了公式（I）中的组胺H3拮抗剂，其中R1是苯并咪唑酮衍生物，M1和M2是可选择地取代的碳或氮，R2包括可选择地取代的芳基或杂环基，其余变量如规范中所定义。还揭示了包括公式（I）化合物的药物组合物。还揭示了使用公式（I）化合物治疗各种疾病或症状的方法，例如过敏、过敏引起的气道反应和充血（例如，鼻塞）的方法。还揭示了使用公式（I）化合物与H1受体拮抗剂结合治疗各种疾病或症状的方法，例如过敏、过敏引起的气道反应和充血（例如，鼻塞）。
• [EN] QUINOLONE ANTIBACTERIAL AGENTS<br/>[FR] AGENTS ANTIBACTERIENS A BASE DE QUINOLONE
  申请人：WARNER LAMBERT CO

  公开号：WO2005026165A1

  公开（公告）日：2005-03-24

  Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including use as antibacterial agents.

  公开了式I的化合物及其制备方法。进一步公开了制备式I生物活性化合物的方法，以及包括式I化合物的药用可接受组合物。本文公开的式I化合物可用于各种应用，包括用作抗菌剂。
• Thiadiazoles useful in the treatment of senile dementia
  申请人：Merck Sharpe & Dohme Ltd.

  公开号：US05405853A1

  公开（公告）日：1995-04-11

  A class of novel thiadiazoles, substituted on one of the ring carbon atoms with a non-aromatic azacyclic or azabicyclic ring system, and substituted on the other ring carbon atom with a substituent of low lipophilicity, or a hydrocarbon substituent; are potent muscarinic agonists, and have good CNS penetrability. The compounds are therefore useful in the treatment of neurological and mental illnesses, and are also of benefit in the treatment of severe painful conditions.

  一类新型噻二唑类化合物，其中一个环上的碳原子被非芳香性氮杂环或氮杂双环系统取代，另一个环上的碳原子被低亲脂性取代基或烃基取代；这些化合物是有效的肌肉收缩素激动剂，并具有良好的中枢神经系统穿透性。因此，这些化合物在治疗神经和精神疾病方面具有用途，并且在治疗严重疼痛症状方面也具有益处。
• Nitrogen heterocycle biaryls for osteoporosis and other diseases
  申请人：Letourneau John Jeffrey

  公开号：US20050222203A1

  公开（公告）日：2005-10-06

  Nitrogen heterocycle biaryls having a carboxylate terminus are useful for treating endometriosis, osteoporosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity. Compounds of formula: are disclosed. A representative example is

  氮杂环联苯具有羧酸末端，可用于治疗子宫内膜异位症、骨质疏松症、血管成形术后再狭窄、类风湿关节炎、癌症、黄斑变性和肥胖症。 公开了以下化合物的结构： 代表性示例是
• Pyrrolidines
  申请人：Dack Kevin N.

  公开号：US20100120793A1

  公开（公告）日：2010-05-13

  This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutically acceptable derivatives thereof, to their use in medicine, to compositions containing them, and to processes for their preparation. It also relates to intermediates used in the preparation of such compounds and derivatives. In particular the compounds of formula (I) are useful for the treatment of EP2-mediated conditions, such as endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), chronic pelvic pain syndrome.

  这项发明涉及一类式(I)的吡咯烷化合物及其药学上可接受的衍生物，它们在医学上的应用，含有它们的组合物，以及它们的制备方法。它还涉及用于制备这类化合物和衍生物的中间体。特别是式(I)的化合物对于治疗EP2介导的疾病非常有用，如子宫内膜异位症、子宫肌瘤（平滑肌瘤）、月经过多、子宫腺肌病、原发性和继发性痛经（包括性交疼痛、排便疼痛和慢性盆腔疼痛症状）、慢性盆腔疼痛综合征。